{"id":"hx008","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL4650472","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HX008 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the inhibitory PD-L1/PD-1 axis that tumors exploit to evade immune surveillance. By preventing this interaction, the drug restores T-cell activation and proliferation, enabling the immune system to recognize and eliminate cancer cells. This mechanism is characteristic of immune checkpoint inhibitors used across multiple cancer types.","oneSentence":"HX008 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:27.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT07394244","phase":"PHASE2","title":"Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-09","conditions":"Cutaneous Squamous Cell Carcinoma (CSCC)","enrollment":38},{"nctId":"NCT04616443","phase":"PHASE1, PHASE2","title":"OH2 Injection in Combination With HX008 for Melanoma.","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2020-12-01","conditions":"Melanoma","enrollment":60},{"nctId":"NCT04868162","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-04-23","conditions":"Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","enrollment":116},{"nctId":"NCT07054307","phase":"PHASE1","title":"MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jiyan Liu","startDate":"2025-07-30","conditions":"Penile Cancer","enrollment":10},{"nctId":"NCT03866525","phase":"PHASE1, PHASE2","title":"OH2 Oncolytic Viral Therapy in Solid Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2019-04-02","conditions":"Solid Tumor, Gastrointestinal Cancer","enrollment":300},{"nctId":"NCT04508803","phase":"PHASE2","title":"Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-09-14","conditions":"Treatment Efficacy","enrollment":37},{"nctId":"NCT05688605","phase":"PHASE1, PHASE2","title":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2022-06-30","conditions":"Advanced Solid Tumors","enrollment":18},{"nctId":"NCT05652894","phase":"PHASE3","title":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-20","conditions":"Metastatic Colorectal Cancer","enrollment":190},{"nctId":"NCT05647954","phase":"PHASE3","title":"A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-31","conditions":"Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms","enrollment":350},{"nctId":"NCT05338957","phase":"PHASE1, PHASE2","title":"A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2022-08-05","conditions":"Advanced Malignant Solid Tumors","enrollment":30},{"nctId":"NCT05070221","phase":"PHASE1","title":"Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-10-01","conditions":"Melanoma Stage IV","enrollment":30},{"nctId":"NCT05068453","phase":"PHASE1","title":"Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-10-01","conditions":"Melanoma Stage IV","enrollment":15},{"nctId":"NCT04825392","phase":"PHASE1","title":"A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2019-09-05","conditions":"Advanced Solid Tumor","enrollment":30},{"nctId":"NCT03704246","phase":"PHASE2","title":"Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2018-09-30","conditions":"Advanced Solid Tumor","enrollment":123},{"nctId":"NCT04756934","phase":"PHASE1","title":"A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma","status":"UNKNOWN","sponsor":"Taizhou HoudeAoke Biomedical Co., Ltd.","startDate":"2020-08-20","conditions":"Melanoma","enrollment":63},{"nctId":"NCT04750083","phase":"PHASE2, PHASE3","title":"HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2020-09-25","conditions":"Nonsquamous Non-small Cell Lung Cancer","enrollment":700},{"nctId":"NCT04750382","phase":"PHASE1, PHASE2","title":"A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2019-07-15","conditions":"Triple-negative Breast Cancer","enrollment":31},{"nctId":"NCT04749485","phase":"PHASE2","title":"A Study of HX008 for the Treatment of Patients With Malignant Melanoma","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2018-11-08","conditions":"Melanoma","enrollment":119},{"nctId":"NCT04741165","phase":"PHASE2","title":"Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2021-01-07","conditions":"Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT04738630","phase":"PHASE2","title":"Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2020-09-25","conditions":"Bladder Cancer","enrollment":110},{"nctId":"NCT04486651","phase":"PHASE3","title":"HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2020-09-16","conditions":"Stomach Cancer","enrollment":560},{"nctId":"NCT04574817","phase":"PHASE2","title":"Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2020-12-28","conditions":"Anaplastic Thyroid Cancer","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HX008","genericName":"HX008","companyName":"Taizhou Hanzhong biomedical co. LTD","companyId":"taizhou-hanzhong-biomedical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HX008 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":9,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}